ViviCells International, Inc. (VCII) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerViviCells International, Inc. (VCII) trades at $0.0001. ViviCells International, Inc. operates as a stem cell preservation company. Formerly Tropical Beverage Inc., the company shifted its focus in 2008 and is based in Evanston, Illinois. Sector: Utilities.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for VCII: VCII does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
ViviCells International, Inc. (VCII) Utility Operations & Dividend Profile
ViviCells International, Inc., established in 1995 and based in Evanston, Illinois, focuses on stem cell preservation. Formerly Tropical Beverage Inc., the company transitioned in 2008. With a negative profit margin of -8.6% and a debt-to-equity ratio of 107.13, the company operates within the utilities-renewable sector.
What Is the Investment Thesis for VCII?
Investing in ViviCells International, Inc. presents a speculative opportunity given its current financial metrics and limited publicly available information. The company's negative profit margin of -8.6% indicates it is not currently profitable, and its high beta of 45.79 suggests extreme volatility compared to the market. The debt-to-equity ratio of 107.13 signals a significant reliance on debt financing. A potential growth catalyst lies in expanding its stem cell preservation services to new markets or developing innovative preservation technologies. However, the lack of a dividend yield means investors are solely reliant on capital appreciation. The company's success hinges on its ability to achieve profitability and manage its debt effectively.
Based on FMP financials and quantitative analysis
VCII Key Highlights
Market capitalization of $0.00B indicates a micro-cap or nano-cap company with limited market presence.
- Negative profit margin of -8.6% suggests the company is currently operating at a loss.
- Gross margin of 22.2% indicates the company retains a portion of revenue after accounting for the cost of goods sold, but this is insufficient to achieve profitability given current operating expenses.
- Debt-to-equity ratio of 107.13 suggests a high level of financial leverage, increasing financial risk.
- Beta of 45.79 indicates extremely high volatility relative to the overall market, suggesting a speculative investment.
Who Are VCII's Competitors?
VCII is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RAIN Rain Enhancement Technologies Holdco, Inc. | $0.77 | -7.70% | $7.71M | — |
| NXXT NextNRG Inc. | $0.73 | -0.86% | $11.5M | — |
| WAVE Eco Wave Power Global AB (publ) | $5.84 | +0.69% | $34.1M | — |
| ELLO Ellomay Capital Ltd. | $20.81 | -7.12% | $287M | 31 5-pillar |
| NRGV Energy Vault Holdings, Inc. | $3.94 | +1.29% | $714M | — |
| FLNC Fluence Energy, Inc. | $7.61 | +0.53% | $1.40B | — |
| SMR NuScale Power Corporation | $7.75 | -0.51% | $2.31B | — |
| RNW ReNew Energy Global Plc | $6.84 | +0.15% | $2.49B | 38 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VCII's Key Strengths?
Focus on a niche market (stem cell preservation).
- Potential for growth in the regenerative medicine field.
- Established presence since 1995.
- Strategic location in Evanston, Illinois.
What Are VCII's Weaknesses?
Negative profit margin.
- High debt-to-equity ratio.
- Limited publicly available information.
- Small market capitalization.
What Are the Key Risks for VCII?
Negative return on equity (-0.7%) — the business is not currently generating profit on shareholder capital.
- Competition from established biotechnology companies with greater resources and expertise.
- Technological advancements rendering current preservation methods obsolete.
- Regulatory changes impacting stem cell research and preservation.
- The company's negative profit margin and high debt-to-equity ratio pose significant financial risks.
- Limited liquidity and the OTC Other listing status increase the volatility and risk of investing in VCII.
What Are VCII's Competitive Advantages?
- Specialized expertise in stem cell preservation techniques.
- Proprietary preservation technologies (if any).
- Established relationships with research institutions (if any).
What Does VCII Do?
ViviCells International, Inc., originally incorporated in 1995 as Tropical Beverage Inc., underwent a significant transformation in May 2008 when it rebranded and shifted its focus to stem cell preservation. Based in Evanston, Illinois, the company operates within the utilities sector, specifically targeting the renewable energy segment due to the nature of stem cell preservation requiring specialized, sustainable energy solutions. The company's evolution from a beverage company to a stem cell preservation entity reflects a strategic pivot towards a niche market with potential long-term growth. ViviCells aims to provide advanced preservation services, potentially catering to both research institutions and individual clients seeking to preserve stem cells for future medical applications. While specific details on their preservation technologies and service offerings are limited, the company's core business revolves around maintaining the viability and integrity of stem cells through specialized processes and storage solutions. The company's current market position is not clearly defined due to limited information, but its focus on stem cell preservation suggests a targeted approach within the broader biotechnology and healthcare landscape.
What Products and Services Does VCII Offer?
- Preserves stem cells using specialized techniques.
- Provides storage solutions for stem cell samples.
- Caters to research institutions requiring stem cell preservation.
- Potentially serves individual clients seeking stem cell preservation.
- Maintains the viability and integrity of stem cells.
- Operates within the biotechnology and healthcare sectors.
How Does VCII Make Money?
- Generates revenue through stem cell preservation services.
- Potentially charges fees for storage and maintenance of stem cell samples.
- May offer customized preservation solutions for specific client needs.
What Industry Does VCII Operate In?
ViviCells International, Inc. operates within the utilities sector, specifically in the renewable energy segment due to the power requirements of stem cell preservation. The global utilities market is undergoing a significant transformation, driven by the increasing demand for sustainable and renewable energy sources. The stem cell preservation market is a niche segment within the broader biotechnology and healthcare industries, driven by advancements in regenerative medicine and personalized healthcare. Competition in this niche is likely to include specialized biotech firms and research institutions with stem cell storage capabilities. The company's success depends on its ability to establish a competitive advantage through innovative preservation technologies and strategic partnerships.
Who Are VCII's Key Customers?
- Research institutions conducting stem cell research.
- Biotechnology companies utilizing stem cells for therapeutic development.
- Individuals seeking to preserve their stem cells for future medical applications.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
ViviCells International, Inc. operates in the Utilities sector. It is headquartered in Evanston, US. The company is led by CEO Kenneth S. Wulwick. VCII has traded publicly since 1998.
Key Financial Metrics
Return on equity for ViviCells International, Inc. stands at -0.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.6%, showing how much profit it generates from its asset base. Its earnings yield is -45.6%, the inverse of the P/E and a quick read on earnings relative to price.
VCII Financials
VCII Latest News
No recent news available for VCII.
VCII Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for VCII.
Price Targets
Wall Street price target analysis for VCII.
VCII MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for VCII; grades run from A+ (80-100) to F (below 30).
VCII OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ViviCells International, Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be subject to greater regulatory scrutiny. Investing in OTC Other stocks carries significant risks due to the potential for fraud, lack of liquidity, and limited information available to investors. These stocks are generally considered highly speculative.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in VCII.
- Low liquidity can make it difficult to buy or sell shares.
- OTC Other stocks are subject to greater regulatory scrutiny and potential for fraud.
- The company's financial condition may be unstable.
- The company may not meet the listing requirements of higher-tier exchanges.
- Verify the company's registration and compliance with regulatory requirements.
- Obtain and review the company's financial statements (if available).
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and their track record.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before making any investment decisions.
- Check for any history of regulatory actions or legal disputes.
- Company has been in operation since 1995.
- Company headquarters are located in Evanston, Illinois.
- Company has a registered business name.
- Company changed its name and business focus in 2008, indicating a strategic shift.
What Investors Ask About ViviCells International, Inc. (VCII) — Utilities
What are the main risks for VCII?
The main risks for ViviCells International, Inc. include its negative profit margin, high debt-to-equity ratio, and limited liquidity due to its OTC Other listing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on ViviCells International, Inc. due to its OTC Other listing and lack of analyst coverage.
- Financial data is based on the most recent available information, which may be outdated.